SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: j_fir2 who wrote (1845)2/26/1999 11:19:00 AM
From: rkrw   of 10280
 
Allegra is selling well and has served its purpose of providing a safe and equally effective alternative to Seldane. Considering its been on the market for but two years and considering that sales of Seldane had crashed prior to Allegra's introduction to levels well below current Allegra sales, I'd call Allegra's launch successful. Should Sepracor begin earning royalties on sales at the rumored to be 8% level, they should see royalty streams of at least $40M based on a conservative $500M in 2002 sales, which is essentially the sales level today. Take a still conservative $600-$700M in 2002 sales and royalties jump to $48-$56M. Of course, the patent interference case has yet to be resolved.

From Albany Molecular's S1:
Sales of fexofenadine HCl in the U.S. were approximately $212 million for the year ended December 31, 1997 and approximately $339 million for the nine months ended September 30, 1998.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News